Arch Biopartners Inc.
CNSX : ACH
OTC : FOIFF

Arch Biopartners Inc.

July 18, 2011 08:55 ET

Arch Biopartners Hires Investor Relations Firm

TORONTO, ONTARIO--(Marketwire - July 18, 2011) - Arch Biopartners Inc ("Arch" or the "Company")(CNSX:ACH)(OTC:FOIFF) announced today it has retained the services of Renmark Financial Communications Inc. (Renmark") to perform investor relations activities.

In consideration of the services to be provided, the Company has agreed to a one year contract starting August 1st, 2011 and will pay Renmark a monthly fee starting at $4000 per month. The contract can be terminated by either party with 30 days notice. Renmark does not have any interest, directly or indirectly, in Arch Biopartners Inc. or its securities, or any right or intent to acquire such an interest.

About Arch Biopartners

Arch Biopartners is a portfolio based biotechnology company established to develop new products and technology for sale to pharmaceutical and industrial companies.

For more information on the Company, please consult the other public documents filed on SEDAR at www.sedar.com.

The Company's website address is: www.archbiopartners.com.

Forward-Looking Statements

All statements, other than statements of historical fact, in this news release are forward looking statements that involve various risks and uncertainties, including, without limitation, statements regarding the future plans and objectives of the Company. There can be no assurance that such statements will prove to be accurate. Actual results and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral forward-looking statements are based on the estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. The Company assumes no obligation to update forward-looking statements should circumstances or management's estimates or opinions change.

The CNSX has not reviewed and does not accept responsibility for the adequacy of this release.

Contact Information